ScoreWhy is Prelude Therapeutics, Inc. ?
1
With a growth in Net Sales of INF%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 3 consecutive quarters
- NET SALES(HY) At USD 10.22 MM has Grown at 155.5%
- OPERATING CASH FLOW(Y) Highest at USD -43.75 MM
- OPERATING PROFIT(Q) Highest at USD -13.79 MM
2
Rising Promoter Confidence
- Promoters have increased their stake in the company by 13.2% over the previous quarter and currently hold 31.36% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
3
Market Beating Performance
- The stock has generated a return of 583.77% in the last 1 year, much higher than market (S&P 500) returns of 20.21%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Prelude Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Prelude Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Prelude Therapeutics, Inc.
490.96%
0.22
207.29%
S&P 500
20.6%
1.55
13.08%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
67.39%
EBIT Growth (5y)
-26.10%
EBIT to Interest (avg)
-118.58
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
0.09
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
52.49%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.80
EV to EBIT
-0.88
EV to EBITDA
-0.89
EV to Capital Employed
-2.88
EV to Sales
7.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-144.96%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -33.24 MM
ROCE(HY)
Highest at -57.73%
RAW MATERIAL COST(Y)
Fallen by -9,381% (YoY
NET SALES(9M)
Higher at USD 15.92 MM
PRE-TAX PROFIT(Q)
At USD -13.92 MM has Grown at 55.43%
NET PROFIT(Q)
At USD -13.92 MM has Grown at 55.43%
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Prelude Therapeutics, Inc.
Net Sales
At USD 15.92 MM has Grown at 298.1%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -33.24 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD -13.92 MM has Grown at 55.43%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -13.92 MM has Grown at 55.43%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Sales
Higher at USD 15.92 MM
than preceding 12 month period ended Jun 2026MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by -9,381% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
